IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v12y2021i1d10.1038_s41467-021-26499-y.html
   My bibliography  Save this article

A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses

Author

Listed:
  • Weina Sun

    (Icahn School of Medicine at Mount Sinai)

  • Yonghong Liu

    (Icahn School of Medicine at Mount Sinai)

  • Fatima Amanat

    (Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount Sinai)

  • Irene González-Domínguez

    (Icahn School of Medicine at Mount Sinai)

  • Stephen McCroskery

    (Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount Sinai)

  • Stefan Slamanig

    (Icahn School of Medicine at Mount Sinai)

  • Lynda Coughlan

    (University of Maryland School of Medicine, Department of Microbiology and Immunology
    University of Maryland School of Medicine, Center for Vaccine Development and Global Health (CVD))

  • Victoria Rosado

    (Icahn School of Medicine at Mount Sinai)

  • Nicholas Lemus

    (Icahn School of Medicine at Mount Sinai)

  • Sonia Jangra

    (Icahn School of Medicine at Mount Sinai
    Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai)

  • Raveen Rathnasinghe

    (Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount Sinai
    Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai)

  • Michael Schotsaert

    (Icahn School of Medicine at Mount Sinai
    Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai)

  • Jose L. Martinez

    (Icahn School of Medicine at Mount Sinai)

  • Kaori Sano

    (Icahn School of Medicine at Mount Sinai)

  • Ignacio Mena

    (Icahn School of Medicine at Mount Sinai
    Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai)

  • Bruce L. Innis

    (PATH, Center for Vaccine Access and Innovation)

  • Ponthip Wirachwong

    (The Government Pharmaceutical Organization)

  • Duong Huu Thai

    (Institute of Vaccines and Medical Biologicals)

  • Ricardo Das Neves Oliveira

    (Instituto Butantan)

  • Rami Scharf

    (PATH, Center for Vaccine Access and Innovation)

  • Richard Hjorth

    (PATH, Center for Vaccine Access and Innovation)

  • Rama Raghunandan

    (PATH, Center for Vaccine Access and Innovation)

  • Florian Krammer

    (Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount Sinai)

  • Adolfo García-Sastre

    (Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount Sinai
    Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount Sinai)

  • Peter Palese

    (Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount Sinai)

Abstract

Rapid development of COVID-19 vaccines has helped mitigating SARS-CoV-2 spread, but more equitable allocation of vaccines is necessary to limit the global impact of the COVID-19 pandemic and the emergence of additional variants of concern. We have developed a COVID-19 vaccine candidate based on Newcastle disease virus (NDV) that can be manufactured at high yields in embryonated eggs. Here, we show that the NDV vector expressing an optimized spike antigen (NDV-HXP-S) is a versatile vaccine inducing protective antibody responses. NDV-HXP-S can be administered intramuscularly as inactivated vaccine or intranasally as live vaccine. We show that NDV-HXP-S GMP-produced in Vietnam, Thailand and Brazil is effective in the hamster model. Furthermore, we show that intramuscular vaccination with NDV-HXP-S reduces replication of tested variants of concerns in mice. The immunity conferred by NDV-HXP-S effectively counteracts SARS-CoV-2 infection in mice and hamsters.

Suggested Citation

  • Weina Sun & Yonghong Liu & Fatima Amanat & Irene González-Domínguez & Stephen McCroskery & Stefan Slamanig & Lynda Coughlan & Victoria Rosado & Nicholas Lemus & Sonia Jangra & Raveen Rathnasinghe & Mi, 2021. "A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses," Nature Communications, Nature, vol. 12(1), pages 1-14, December.
    • Handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-26499-y
    DOI: 10.1038/s41467-021-26499-y
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-021-26499-y
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-021-26499-y?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Kaori Sano & Disha Bhavsar & Gagandeep Singh & Daniel Floda & Komal Srivastava & Charles Gleason & Juan Manuel Carreño & Viviana Simon & Florian Krammer, 2022. "SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals," Nature Communications, Nature, vol. 13(1), pages 1-8, December.
    2. Carlos Ávila-Nieto & Júlia Vergara-Alert & Pep Amengual-Rigo & Erola Ainsua-Enrich & Marco Brustolin & María Luisa Rodríguez de la Concepción & Núria Pedreño-Lopez & Jordi Rodon & Victor Urrea & Edwar, 2024. "Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection," Nature Communications, Nature, vol. 15(1), pages 1-18, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-26499-y. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.